Our Mastery
Testimonial
- "Amazing success ratio in such uncertain market and paid service is very affordable ...Good job done by your team...keep it up guys."
-Venkat (Chennai)
Party Plot Owner - "I am trading in stock market since last 8 years; I have subscribed services from many advisory companies. Conclusion is that no one can provide 100% accuracy in this NSE market. But accuracy of intraday tips from this firm is the highest among all share tips companies" Rahul Varma (Mumbai)
Owner of an Insurance Firm - "I have taken free trial of intraday tips for 2 days and 80% call is profitable. Then I have subscribed paid membership for trading advice and now I am quite satisfied with services. Important thing is do not think more; Just trade what you are suggested" -Kevin Patel (Ahmedabad)
BDM at IT Company - "Made Good Profit in the Intraday, Jackpot Calls, F&o Tips. Overall Service is very good. Especially I like your Fast tips Sms Service & Exit Call System. Your tips have very good performance." -Manoj Arora (Delhi)
CEO of Real Estate Company
Dr Reddys Laboratories Ltd share price today (on 22 March 2023).
We Provide Best stock tips for Dr Reddys Laboratories Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Dr Reddys Laboratories Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.
Get Free Stock Tips for Dr Reddys Laboratories Ltd
BSE: 500124 | NSE: DRREDDY | ISIN: INE089A01023 Market Cap: [Rs.Cr.] 28,813 | Face Value: [Rs.] 5 Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
In 1984, Dr Anji Reddy established Dr. Reddy's Laboratories.
Dr Reddy's is a global, vertically integrated pharmaceutical company. As a fully integrated pharmaceutical company, their purpose is to provide affordable and innovative medicines through our three core businesses:
Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses;
Global Generics, which includes branded and unbranded generics; and Proprietary
Dr Reddy's Laboratories Ltd is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. The company offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, differentiated formulations and News Chemical Entities (NCEs) through their three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Their Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and paediatrics. Their major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. Dr Reddy's Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa. In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business.
In the year 1990, they exported Norfloxacin and Ciprofloxacin to Europe and Far East. In the year 1991, they commenced formulation exports to Russia. In the year 1993, the company established Dr. Reddy's Research Foundation and initiated drug discovery programme. In the year 1994, they finished dosages facility established to cater to highly regulated markets such as the US. In the year 1995, the company set up joint venture in Russia. In the year 1997, they filled first ANDA with the United States Food and Drug Administration for Ranitidine. In the year 1999, the company acquired American Remedies Ltd, a pharmaceutical company based in India. In the year 2000, Cheminor Drugs Ltd, a group company merged with the company and thus the company became India's third largest pharma company. In the year 2001, the company launched Fluoxetine capsules.
They became the first Indian company to win 180-day exclusivity for a generic drug in the US. Also, they launched their first generic product, Ranitidine, in the US market. In the year 2002, the company made their first overseas acquisition of BMS Laboratories Limited and Meridian Healthcare in UK. In the year 2003, they launched Ibuprofen, first generic product to be marketed under the 'Dr. Reddy's' label in the US. In the year 2005, they acquired Roche's API Business at its manufacturing site in Mexico. In the year 2006, the company acquired Betapharm the fourth largest generics company in Germany for a total enterprise value of Rs 480 million. In the year 2007, the company launched Reditux - the world's first biosimilar MAb - for the treatment of Non Hodgkins Lymphoma. Also, they became India's leading and most profitable pharmaceutical company.
During the year 2008-09, the company acquired DowPharma's small molecules business in UK under Chirotech Technology Ltd, BASF Corporation's manufacturing facility at Shreveport in Louisiana, USA under Dr. Reddy's Laboratories Louisiana LLC and Jet Generici SRL, a company engaged in the sale of generic finished dosages in Italy. In addition, Perlecan Pharma Pvt Ltd, Macred India Pvt Ltd and Dr. Reddy's Laboratories ILAC Ticaret also became subsidiary of the company. During the year 2009-10, Dr. Reddy's Pharma SEZ Ltd was incorporated as a wholly-owned subsidiary of the company for the purpose of formulation manufacturing at Special Economic Zone and Perlecan Pharma Pvt Ltd was amalgamated with the company. Further, the company acquired the balance stake of 30% in Dr. Reddy's (Australia) Pty Ltd.
The company filed 12 Abbreviated New Drug Applications (ANDAs) in US including six Para IV filing during the year. During the year 2010-11, the company acquired GlaxoSmithKline's (GSK) oral penicillin manufacturing facility located in Tennessee, USA. This allows the company to enter theUS penicillin-containing antibacterial market segment through brands such as Augmentin and Amoxil, and serve the needs of customers through manufacturing and other capabilities that did not previously exist within the company. Also, they increased the stake in the South African joint venture company to 100% after acquiring the 40% stake of the partner. During the year, the company launched Cresp in India, the first biosimilar darbepoetin alfa in the world.
In March 2011, they launched Peg-grafeelTM in India in the form of an affordable pegfilgrastim, which is used to stimulate the bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. Peg-grafeelTM During the year, Idea2Enterprises (India) Pvt Ltd, Dr. Reddy's Laboratories Romania SRL, I-Ven Pharma Capital Ltd, Dr. Reddy's Laboratories Tennessee LLC and Dr. Reddy's Venezuela C.A. became wholly-owned subsidiaries of the company. Further, Dr. Reddy's Laboratories (Proprietary) Ltd also became wholly-owned subsidiary by virtue of purchase of its balance 40% stake by the company. Also, Macred India Pvt Ltd ceased to be a subsidiary of the company.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 31.76%, from INR 7,549.2 tens of millions to INR 9,946.8 tens of millions. Operating result increased from INR 1,506.3 tens of millions to INR 2,483.9 tens of millions which means 64.90% change. The results of the period increased 43.78% reaching INR 1,436.2 tens of millions at the end of the period against INR 998.9 tens of millions last year. Return on equity (Net income/Total equity) went from 24.78% to 28.79%, the Return On Asset (Net income / Total Asset) went from 15.36% to 12.68% and the Net Profit Margin (Net Income/Net Sales) went from 13.23% to 14.44% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 226.98% compared to 161.27% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 2.01 to 2.21 when compared to the previous year.
Nse Listed Companies with Live Charts
with live charts starting with that Alphabet.)
| A | B | C | D | E | F | G | H | I | J |
| K | L | M | N | O | P | Q | R | S | T |
| U | V | W | X | Y | Z |
